This site is intended for healthcare professionals
Journals
  • Home
  • /
  • Journals
  • /
  • Non-Hodgkin lymphoma
  • /
  • Idelalisib for the treatment of chronic lymphocyti...
Journal

Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.

Read time: 1 mins
Published:1st Sep 2016
Author: Barrientos JC.
Source: Future Oncology
Availability: Pay for access, or by subscription
Ref.:Future Oncol. 2016;12(18):2077-94.
DOI:10.2217/fon-2016-0003

Idelalisib is a first-in-class selective oral PI3Kδ inhibitor for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma, a predominantly elderly population with high comorbidity. The drug promotes apoptosis in primary CLL cells ex vivo, independent of common prognostic markers and inhibits CLL cell homing, migration and adhesion to cells in the microenvironment. Idelalisib has shown efficacy with acceptable safety as monotherapy and combination therapy in relapsed/refractory CLL. Idelalisib has clinical activity in patients with CLL with del(17p). The development of other novel B-cell-targeted agents provides the opportunity to evaluate additional idelalisib treatment combinations for their potential to further improve outcomes in CLL/small lymphocytic lymphoma.

 

Read abstract on library site

Access full article